Design and Development of Therapies using Chimeric Antigen Receptor-Expressing T cells
Explore this paper's citation graph
Summary
The value of adding additional engineering features to CAR‐T cells, irrespective of their target, to render them better suited to function in the tumor environment, and the safety of these heavily modified cells may be maintained are shown.
- Type
- review
- Published
- 2014-01-01
- Cited by
- 500
- References
- 210
- Access
- Open access
- OpenAlex
- https://openalex.org/W1977949161
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:23718478
Keywords
Chimeric antigen receptor, Antigen, Biology, Effector, Major histocompatibility complex
References
- Ligand-mediated cytolysis of tumor cells: Use of heregulin-ζ chimeras to redirect cytotoxic T lymphocytes
- In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cells
- Stem-like tumor initiating cells isolated from IL13Rα2-expressing gliomas are targeted and killed by IL13-zetakine redirected T cells
- Flexible Targeting of ErbB Dimers That Drive Tumorigenesis by Using Genetically Engineered T Cells
- In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
- IL-15 and IL-2: a matter of life and death for T cells in vivo
- Cancer associated fibroblasts: the dark side of the coin.
- T Cell Retargeting with MHC Class I-Restricted Antibodies: The CD28 Costimulatory Domain Enhances Antigen-Specific Cytotoxicity and Cytokine Production1
- Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product.
- All in the Stroma: Cancer's Cosa Nostra
- Primary Human T Lymphocytes Engineered with a Codon-Optimized IL-15 Gene Resist Cytokine Withdrawal-Induced Apoptosis and Persist Long-Term in the Absence of Exogenous Cytokine1
- TGFβ signaling in health and disease
- Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors.
- Chimeric Antigen Receptors for T cell Immunotherapy: Current Understanding and Future Direction
- Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor1
- Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.
- A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity
- Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
- IL-2, Regulatory T Cells, and Tolerance
- Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma.
Cited by
- CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma
- Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells
- Modulating T-cell-based cancer immunotherapy via particulate systems
- Chimeric Antigen Receptor T Cell Bearing Herpes Virus Entry Mediator Co-Stimulatory Signal Domain Exhibits Exhaustion-Resistant Properties
- Adolescent and young adult patients with cancer: a milieu of unique features
- T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice.
- Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors
- Peripheral Blood–Derived Virus-Specific Memory Stem T Cells Mature to Functional Effector Memory Subsets with Self-Renewal Potency
- CAR T-cell therapy: toxicity and the relevance of preclinical models.
- Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications
- Adoptive T‐cell therapy for cancer: The era of engineered T cells
- T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression
- Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity
- Chimeric antigen receptor T cells for cancer immunotherapy.
- K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic-T Lymphocytes in vivo
- Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors
- Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer.
- Novel therapies in AML: reason for hope or just hype?
- Translational research in oncology—10 years of progress and future prospects
- Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
Related papers
- Crucial Roles of Effectors in Interactions between Horticultural Crops and Pathogens
- Prediction of effector proteins and their implications in pathogenicity of phytopathogenic filamentous fungi: A review.
- Remote homology clustering identifies lowly conserved families of effector proteins in plant-pathogenic fungi
- "Order from disordered": Potential role of intrinsically disordered regions in phytopathogenic oomycete intracellular effector proteins.
- Fungal Effectoromics: A World in Constant Evolution
- All Roads Lead to Susceptibility: The Many Modes of Action of Fungal and Oomycete Intracellular Effectors
- Fungal effectors and plant susceptibility.
- Form and function of fungal and oomycete effectors